MediaMedic

Omission of surgery in early breast cancer: Are we ready for a paradigm shift?

By Mourabit Halima 2025.05.19

In a recent ESSO Research Academy survey led by Carmela Caballero and co-authored by Prof. Isabel T. Rubio, Prof. Evandro de Azambuja, and Prof. Stuart A. McIntosh, both clinicians and…

Advancing precision oncology with metabolomics and machine learning

By Yin, Jiale 2025.05.19

A new study led by Dr. Rafael Nambo Venegas and colleagues, published in Metabolomics (Feb 2025), presents a high-accuracy predictive model for forecasting response to neoadjuvant therapy in breast cancer…

Risk-based breast cancer screening: A shift toward personalized prevention

By Mourabit Halima 2025.05.19

In a recent study published in December 2024, Professor Isabel Rubio and her colleagues critically examined the limitations of current age-based breast cancer screening programs, which remain standard in most…

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

By Mourabit Halima 2025.05.14

At ESCMID Global 2025, Infectious Disease Frontier interviewed Dr. Francesco Cogliati Dezza to explore the renewed clinical relevance of temocillin. With resistance to broad-spectrum antibiotics on the rise, temocillin is…

Professor Li Zhang’s Team Publishes Again in Nature Medicine

By Mourabit Halima 2025.05.12

On April 10, 2025, a research team led by Professor Li Zhang and Professor Wenfeng Fang from Sun Yat-sen University Cancer Center published a significant study in the world-renowned journal…

Mok Talk | Lung Cancer Leadership, Innovation, and the Power of Collaboration

By Peng Longmei 2025.05.09

In this special episode of Mok Talk, Professor Tony Mok (The Chinese University of Hong Kong) sits down with three rising oncology experts Professor Yang Xia (Zhejiang University), Professor Wenhua…

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

By Mourabit Halima 2025.05.09

At ESCMID Global 2025, Infectious Disease Frontier sat down with Dr. Francesco Cogliati Dezza to discuss the renewed clinical relevance of temocillin. As resistance to broad-spectrum antibiotics continues to rise,…

Advancing the Diagnosis and Prevention of Congenital CMV: Insights from Dr. Marianne Leruez-Ville

By Dingming Xue 2025.05.08

At ESCMID Global 2025, one of the world’s leading forums for infectious disease and clinical microbiology, congenital cytomegalovirus (CMV) took center stage as experts explored new avenues in screening, prevention,…

Temocillin and the Search for Carbapenem Alternatives: A Conversation with Dr. Francesco Cogliati Dezza at ESCMID Global 2025

By Dingming Xue 2025.05.08

At ESCMID Global 2025, antimicrobial resistance stood out as one of the most pressing topics. As carbapenem resistance rises to alarming levels worldwide, the medical community is urgently seeking viable…

Prof. Lin Visits MGH | Talk with Prof. Lori Wirth on Targeted Therapy for Advanced Thyroid Cancer

By Mourabit Halima 2025.05.08

Join us for an exclusive conversation between Prof. Yansong Lin of Peking Union Medical College Hospital and Prof. Lori Wirth at Massachusetts General Hospital. In this special academic exchange, the…

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology

Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology

CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights

Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference

2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies

CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Omission of surgery in early breast cancer: Are we ready for a paradigm shift?

Advancing precision oncology with metabolomics and machine learning

Risk-based breast cancer screening: A shift toward personalized prevention

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

Professor Li Zhang’s Team Publishes Again in Nature Medicine

Mok Talk | Lung Cancer Leadership, Innovation, and the Power of Collaboration

Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance

Advancing the Diagnosis and Prevention of Congenital CMV: Insights from Dr. Marianne Leruez-Ville

Temocillin and the Search for Carbapenem Alternatives: A Conversation with Dr. Francesco Cogliati Dezza at ESCMID Global 2025

Prof. Lin Visits MGH | Talk with Prof. Lori Wirth on Targeted Therapy for Advanced Thyroid Cancer

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.